Revive Therapeutics Ltd. announced that Dr. Scott Friedman, M.D., will join the company as a Scientific Advisor for cannabinoid-based therapeutics targeting liver diseases. An internationally renowned physician-scientist, Dr. Scott L. Friedman is the Dean for Therapeutic Discovery and Chief of the Division of Liver Diseases, at the Icahn School of Medicine at Mount Sinai. He has performed pioneering research into the underlying causes of scarring, or fibrosis associated with chronic liver disease.